NBY vs. RGC

Last updated Apr 1, 2026

Compare and contrast key facts about NovaBay Pharmaceuticals, Inc. (NBY) and Regencell Bioscience Holdings Limited (RGC).

Performance

NBY vs. RGC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NovaBay Pharmaceuticals, Inc. (NBY) and Regencell Bioscience Holdings Limited (RGC). The values are adjusted to include any dividend payments, if applicable.

NBY vs. RGC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
NBY NovaBay Pharmaceuticals, Inc.	-94.72%	1,319.69%	-91.58%	-89.54%	-85.21%	-34.65%
RGC Regencell Bioscience Holdings Limited	21.10%	16,053.85%	-52.95%	-62.35%	-12.43%	203.33%

Fundamentals

EPS NBY : $0.11 RGC : -$0.01
Total Revenue (TTM) NBY : $2.83M RGC : $0.00
Gross Profit (TTM) NBY : $1.54M RGC : $0.00
EBITDA (TTM) NBY : -$7.73M RGC : -$4.66M

Returns By Period

In the year-to-date period, NBY achieves a -94.72% return, which is significantly lower than RGC's 21.10% return.

NBY

• 1D: 10.37%
• 1M: 3.47%
• YTD: -94.72%
• 6M: -76.72%
• 1Y: -22.94%
• 3Y*: -80.36%
• 5Y*: -79.31%
• 10Y*: -57.87%

RGC

• 1D: 9.00%
• 1M: -3.05%
• YTD: 21.10%
• 6M: 64.60%
• 1Y: 2,931.18%
• 3Y*: 234.24%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NBY vs. RGC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBY

NBY Risk / Return Rank: 50
NBY Sharpe Ratio Rank: 36
NBY Sortino Ratio Rank: 74
NBY Omega Ratio Rank: 75
NBY Calmar Ratio Rank: 33
NBY Martin Ratio Rank: 33

RGC

RGC Risk / Return Rank: 99
RGC Sharpe Ratio Rank: 100
RGC Sortino Ratio Rank: 99
RGC Omega Ratio Rank: 99
RGC Calmar Ratio Rank: 100
RGC Martin Ratio Rank: 100

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBY vs. RGC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NovaBay Pharmaceuticals, Inc. (NBY) and Regencell Bioscience Holdings Limited (RGC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NBY	RGC	Difference
Sharpe ratio Return per unit of total volatility	-0.10	7.76	-7.85
Sortino ratio Return per unit of downside risk	1.81	6.67	-4.86
Omega ratio Gain probability vs. loss probability	1.25	1.84	-0.59
Calmar ratio Return relative to maximum drawdown	-0.26	42.26	-42.52
Martin ratio Return relative to average drawdown	-0.50	54.68	-55.18
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NBY vs. RGC - Sharpe Ratio Comparison

The current NBY Sharpe Ratio is -0.10, which is lower than the RGC Sharpe Ratio of 7.76. The chart below compares the historical Sharpe Ratios of NBY and RGC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NBY	RGC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.10	7.76	-7.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.57	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.17	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	0.52	-0.71

Correlation

The correlation between NBY and RGC is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NBY vs. RGC - Dividend Comparison

NBY's dividend yield for the trailing twelve months is around 268.46%, while RGC has not paid dividends to shareholders.

	TTM	2025
NBY NovaBay Pharmaceuticals, Inc.	268.46%	14.18%
RGC Regencell Bioscience Holdings Limited	0.00%	0.00%

Drawdowns

NBY vs. RGC - Drawdown Comparison

The maximum NBY drawdown since its inception was -100.00%, which is greater than RGC's maximum drawdown of -93.09%. Use the drawdown chart below to compare losses from any high point for NBY and RGC.

Drawdown Indicators

	NBY	RGC	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	-93.09%	-6.91%
Max Drawdown (1Y) Largest decline over 1 year	-98.79%	-86.72%	-12.07%
Max Drawdown (5Y) Largest decline over 5 years	-99.97%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.99%	—	—
Current Drawdown Current decline from peak	-100.00%	-67.40%	-32.60%
Average Drawdown Average peak-to-trough decline	-82.50%	-59.11%	-23.39%
Ulcer Index Depth and duration of drawdowns from previous peaks	51.59%	67.02%	-15.43%

Volatility

NBY vs. RGC - Volatility Comparison

NovaBay Pharmaceuticals, Inc. (NBY) has a higher volatility of 37.42% compared to Regencell Bioscience Holdings Limited (RGC) at 28.69%. This indicates that NBY's price experiences larger fluctuations and is considered to be riskier than RGC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NBY	RGC	Difference
Volatility (1M) Calculated over the trailing 1-month period	37.42%	28.69%	+8.73%
Volatility (6M) Calculated over the trailing 6-month period	187.53%	108.39%	+79.14%
Volatility (1Y) Calculated over the trailing 1-year period	241.32%	383.81%	-142.49%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	139.53%	313.90%	-174.37%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	333.73%	313.90%	+19.83%

Financials